Dragging Ras Back in the Ring

Stephen, Andrew G., Esposito, Dominic, Bagni, Rachel K., McCormick, Frank·2014·Cancer Cell
DOI 10.1016/j.ccr.2014.02.017

Cited by (801)

Items 601–700 of 801

  1. Excavation of FOSL1 in the Ruins of KRAS-Driven Lung Cancer
    Venkateshwar G. Keshamouni · 2018 · American Journal of Respiratory Cell and Molecular Biology
  2. A dataset describing a suite of novel antibody reagents for the RAS signaling network
    Regine M. Schoenherr, Dongqing Huang, Uliana J. Voytovich, Richard G. Ivey, Jacob J. Kennedy, Richard G. Saul, Simona Colantonio, Rhonda R. Roberts, Joseph G. Knotts, Jan A. Kaczmarczyk et al. · 2019 · Scientific Data
  3. Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models
    Shan Lu, Xiao Pan, Eva Volckova, Anjali Shinde, Schuyler R. Fuller, Regina K. Egan, Jianli Ma, Jong Kung, Christopher J. Ott, Aaron N. Hata et al. · 2025 · Molecular Cancer Therapeutics
  4. Why isn’t an oncogenic mutation in KRAS enough to induce and sustain transformation?
    Juan Iovanna, Nelson Dusetti · 2026 · Critical Reviews in Oncology/Hematology
  5. Argonaute 2 modulates EGFR–RAS signaling to promote mutantHRASandNRAS-driven malignancies
    Ronald F. Siebenaler, Seema Chugh, Jessica J. Waninger, Vijaya L. Dommeti, Carson Kenum, Malay K. Mody, Anudeeta Gautam, Nidhi Patel, Alec Chu, Pushpinder Bawa et al. · 2022 · PNAS Nexus
  6. Synergy and anti‐cooperativity in allostery: Molecular dynamics study of WT and oncogenic KRAS‐RGL1
    Aysima Hacisuleyman, Burak Erman · 2023 · Proteins Structure Function and Bioinformatics
  7. Gene signatures from pancreatic cancer tumor and stromal cells predict disease outcome
    Filippos Kottakis, Nabeel M. Bardeesy · 2015 · Nature Genetics
  8. RAS oncogenes direct metastasis
    Μάγδα Σπέλλα, Antonia Marazioti, Kristina A. M. Arendt, Georgios T. Stathopoulos · 2017 · Molecular & Cellular Oncology
  9. 4′‐C‐Aminoethoxy‐Modified DNAs Exhibit Increased Nuclease Resistance, Sustained RNase H Activity, and Inhibition of KRAS Gene Expression
    Yuki Katsuzaki, Ryo Tsukimura, Akash Chandela, Tokuhiro Chano, Yoshihito Ueno · 2022 · Chemistry & Biodiversity
  10. Cancer Spheroid Proliferation Is Suppressed by a Novel Low-toxicity Compound, Pyra-Metho-Carnil, in a Context-independent Manner
    Kazumasa Yoshida, Kensuke Nishi, Shuhei Ishikura, Kazuhiko Nakabayashi, Ryo Yazaki, TAKASHI OHSHIMA, Masahiko Suenaga, Senji Shirasawa, Toshiyuki Tsunoda · 2022 · Anticancer Research
  11. Alisertib exerts KRAS allele‑specific anticancer effects on colorectal cancer cell lines
    Baojun Ren, 高卓维, Kehong Zheng, Yong Yang, Pengfei Su, Qimei Luo, Jing Feng, Luo Zhentao, Yan Geng, Yongle Ju et al. · 2023 · Experimental and Therapeutic Medicine
  12. In silico design of a lipid-like compound targeting KRAS4B-G12D through non-covalent bonds
    Huixia Lu, Zheyao Hu, Jordi Faraudo, Jordi Martí · 2023 · Nanoscale
  13. Adapting recombinant bacterial alkaline phosphatase for nucleotide exchange of small GTPases
    Peter H. Frank, Min Hong, Brianna Higgins, Shelley C. Perkins, Troy E. Taylor, Vanessa E. Wall, Matthew R. Drew, Timothy J. Waybright, William Gillette, Dominic Esposito et al. · 2024 · Protein Expression and Purification
  14. Computational analysis of treatment resistant cancer cells
    Alexandre Matov · 2026 · Frontiers in Cell and Developmental Biology
  15. Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer
    Giampietro Gasparini, Fiamma Buttitta, Mario Rosario D'Andrea, Salvatore Tumolo, Angela Buonadonna, Ida Pavese, Stefano Sergio Cordio, Michele De Tursi, Stefania Mosconi, Luciano Stumbo et al. · 2014 · Neoplasia
  16. Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors
    Na Ye, Qingfeng Xu, Wanwan Li, Pingyuan Wang, Jia Zhou · 2019 · Current Topics in Medicinal Chemistry
  17. Mechanisms and Markers of Clinical Radioresistance
    Michael Sargent Binkley, Maximilian Diehn, Iris Eke, Henning Willers · 2020 · Cancer drug discovery and develogment/Cancer drug discovery and development
  18. KRAS-specific antibody binds to KRAS protein inside colorectal adenocarcinoma cells and inhibits its localization to the plasma membrane
    Kuen Kuen Lam, Yee Syuen Low, Michelle Lo, Michelle Wong, Choong Leong Tang, Emile Tan, Aik Yong Chok, Isaac Seow‐En, Siew Heng Wong, Peh Yean Cheah · 2023 · Frontiers in Oncology
  19. RAS mutations – for better or for worse in multiple myeloma?
    Ellen Leich, Torsten Steinbrunn · 2015 · Leukemia & lymphoma/Leukemia and lymphoma
  20. Comprehensive Validation of Snapback Primer-Based Melting Curve Analysis to Detect Nucleotide Variation in the Codon 12 and 13 of KRAS Gene
    Qunfeng Zhang, Yiqiao Du, Xinju Zhang, Zhihua Kang, Ming Guan, Zhiyuan Wu · 2018 · BioMed Research International
  21. Targeting the Architecture of Deregulated Protein Complexes in Cancer
    Eduard Stefan, Jakob Troppmair, Klaus Bister · 2017 · Advances in protein chemistry and structural biology
  22. Towards an Integrated Understanding of Epidermal Growth Factor Receptor Biology for Radiation Therapy: Integrins Enter
    Henning Willers, Theodore Sunki Hong · 2015 · JNCI Journal of the National Cancer Institute
  23. Identification of Small-Molecule Inhibitors that Block the GTP-Binding Pocket of K-Ras and Other Members of the Ras Superfamily of Small GTPases
    Luca Carta, Rebecca Hutcheson, Carolina L. Bigarella, Sufang Zhang, Simon A. Davis, Michael J. Rudolph, Charles H. Reynolds, Matthias Quick, Theresa M. Williams, Michael Schmertzler et al. · 2025 · Molecular Cancer Therapeutics
  24. Double trouble: cytosolic and nuclear IKKα in cancer
    Kirsty Tinto, Margaret Cunningham, Robin J. Plevin · 2025 · Open Biology
  25. Diffusion-based determination of protein homodimerization on reconstituted membrane surfaces
    Tyler A. Jepson, Jean K. Chung · 2021 · BMB Reports
  26. Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
    Chenyue Xu, Qiongmei Gao, ZhengMing Wu, Weijuan Lou, Xiaoyan Li, Nianhong Wang, Nianhong Wang, Qingquan Li · 2022 · Translational Oncology
  27. Optimized conditions for GTP loading of Ras
    Kimberly J. Vish, Maxum E. Paul, Asha P. Rollins, Titus J. Boggon · 2025 · Journal of Biological Chemistry
  28. p38 links RAS to GATA2
    Christian Baumgärtner, Manuela Baccarini · 2014 · EMBO Reports
  29. Using Drosophila Models and Tools to Understand the Mechanisms of Novel Human Cancer Driver Gene Function
    Santiago Nahuel Villegas, Dolors Ferrés-Marcó, María Domínguez · 2019 · Advances in experimental medicine and biology
  30. Growth Suppression of Cancer Spheroids With Mutated KRAS by Low-toxicity Compounds from Natural Products
    Sayuri Hashimoto, Masayoshi Nagai, Kensuke Nishi, Shuhei Ishikura, Kazuhiko Nakabayashi, Ryo Yazaki, TAKASHI OHSHIMA, Masahiko Suenaga, Senji Shirasawa, Toshiyuki Tsunoda · 2021 · Anticancer Research
  31. ERK2 Mutations Affect Interactions, Localization, and Dimerization
    Clinton A. Taylor, Kevin W. Cormier, Ana Martín-Vega, Svetlana A. Earnest, Steve Stippec, Chonlarat Wichaidit, Melanie H. Cobb · 2023 · Biochemistry
  32. In vivo KRAS G12D/V degradation mediated by CANDDY using a modified proteasome inhibitor
    Satoshi Imanishi, Lijuan Huang, Shoko Itakura, Masamichi Ishizaka, Yoichi Iwasaki, Tomohiro Yamaguchi, Etsuko Miyamoto‐Sato · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  33. Elucidating Ras protein as a dual therapeutic target for inflammation and cancer: a review
    Parmar Keshri Nandan, Sivaraman Jayanthi · 2025 · Discover Oncology
  34. Targeting oncogenic K-RAS mutants with small-molecule degrader XMU-MP-9 through NEDD4-1
    Taoling Zeng, Tingting Jiang, Baoding Zhang, Ting Zhang, Wanjun Dai, Xun Yin, Yunzhan Li, Zhuoran Yu, Caiming Wu, Yaying Wu et al. · 2025 · Acta Pharmaceutica Sinica B
  35. Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models
    Daniela Farias de Nóbrega, Logan C. Eiler, Parmanand Ahirwar, Sonika Nallapu, Urvi P. Rawal, Chelsea L. Crawford, Donald J. Buchsbaum, Adam B. Keeton, Yulia Y. Maxuitenko, Xi Chen et al. · 2025 · Cancers
  36. Impact of KRAS-G12 Mutations on the KRAS-GTP Bound Conformational Dynamics: Structure, Free Energy Barriers and Drugging Pockets
    Zheyao Hu, Zigan Sha, Jordi Martı́, Shujuan Guo, Sheng‐ce Tao · 2026 · JACS Au
  37. Molecular glue degraders: Rational design, specificity engineering, and advanced delivery
    Lieen Ma, Ning Wang, Jingjing Zhu, Lingjie Wu, Shan He, Bin Zhang · 2026 · Acta Pharmaceutica Sinica B
  38. Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy
    Laura D'Alessio‐Sands, Joshua Gaynier, Victoria Michel‐Milian, Ayodeji A. Agbowuro, Christopher M. Brackett · 2025 · Drug Development Research
  39. Targeting MDM2, RAS, and PCNA for cancer targeted therapy: pan-cancer approaches vs. cancer-specific strategies
    Wei Wang, Abigail Alley, Na Sun, Meheret Tadesse, Xinshi Wang, Ruiwen Zhang · 2025 · Frontiers in Pharmacology
  40. Doubling Down on Mutant RAS Can MEK or Break Leukemia
    Zuzana Tóthová, Benjamin L. Ebert · 2017 · Cell
  41. KRAS: Structure, function, and development of anticancer drugs
    Dolly A. Parasrampuria, Alex Yu, Nahor Haddish‐Berhane · 2020 · Elsevier eBooks
  42. Targeting K-Ras Mutations Show Promise Towards Ending Ras’s “Undruggable” Era
    Paul D. Adams, Djamali Muhoza · 2022 · Protein and Peptide Letters
  43. Targeting Oncogenic Driver Mutations in Lung Cancer
    Matthew H. Lee, Fawzi Abu Rous, Alain Borczuk, Stephen V. Liu, Shirish M. Gadgeel, Balázs Halmos · 2023 · Cambridge University Press eBooks
  44. 143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models
    Lansong Xu, Su-xin Zheng, Lianghe Mei, Kexin Yang, Ya‐Fang Wang, Qiang Zhou, Xiangtai Kong, Ming-yue Zheng, Hualiang Jiang, Chengying Xie · 2023 · Acta Pharmacologica Sinica
  45. Cytosolic EpCAM cooperates with H-Ras to regulate epithelial to mesenchymal transition through ZEB1
    Fatma A. Omar, Taylor C. Brown, William E. Gillanders, Timothy P. Fleming, Michael A. Smith, Ross Macrae Bremner, Narendra V. Sankpal · 2023 · PLoS ONE
  46. Probing the Electrostatic Effects of H-Ras Tyrosine 32 Mutations on Intrinsic GTP Hydrolysis Using Vibrational Stark Effect Spectroscopy of a Thiocyanate Probe
    Jackson C. Fink, Danielle Landry, Lauren J. Webb · 2024 · Biochemistry
  47. GradientScanSurv—An exhaustive association test method for gene expression data with censored survival outcome
    Ming Yi, Ruoqing Zhu, Robert M. Stephens · 2018 · PLoS ONE
  48. Therapeutic Targeting of RAS Mutant Cancers
    Edward C. Stites, Kendra V. Paskvan, Shumei Kato · 2022 · Cambridge University Press eBooks
  49. MicroRNA in Breast Cancer — Gene Regulators and Targets for Novel Therapies
    Yunus A. Luqmani, Maitham Abbas Khajah · 2015 · InTech eBooks
  50. Interaction of a novel fluorescent GTP analogue with the small G-protein K-Ras
    Seigo Iwata, Kaori Masuhara, Nobuhisa Umeki, Yasushi Sako, Shinsaku Maruta · 2015 · The Journal of Biochemistry
  51. The Endeavours in RAS Inhibition - the Past, Present, and Future
    Javeena Hussain, Sivapriya Kirubakaran, Srimadhavi Ravi · 2020 · Current Topics in Medicinal Chemistry
  52. Mutant Allele Imbalance in Cancer
    Craig M. Bielski, Barry S. Taylor · 2020 · Annual Review of Cancer Biology
  53. Somatic mutations in colorectal cancer: regional experience
    Nikolai A. Ognerubov, Elena N. Ezhova · 2022 · Consilium Medicum
  54. Ras inhibition by trametinib treatment in Drosophila attenuates gut pathology in females and extends lifespan in both sexes
    Jennifer C. Regan, Yuxuan Lu, Ekin Bolukbasi, Mobina Khericha, Linda Partridge · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
  55. Targeting Hyperactive Ras Signaling in Pediatric Cancer
    Anya L. Levinson, Kevin Shannon, Benjamin J. Huang · 2024 · Cold Spring Harbor Perspectives in Medicine
  56. In Vivo Efficacy of ABHD17 Inhibition Validates the Palmitoylation Cycle as a Therapeutic Target in NRAS -Mutant Cancer
    Matthew Decker, Benjamin J. Huang, Timothy B. Ware, Christopher D. Boone, Michelle Tang, Julia Ybarra, Matthew J. Sale, Rony A. Francois, Aishwarya C. Ballapuram, Katrine A. Taran et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  57. Time-Resolved Crystallography Reveals the Mechanisms of GTP hydrolysis for N-RAS and the Oncogenic Mutants G12C, G12V and Q61L
    Guowu Lin, Paola Zinser Peniche, Xiaohong Zhou, Ulises Santiago, Igor V. Kurnikov, Silvia Russi, Brisa Caroline Alves Chagas, M.E. Sharpe, Dennis P. Stegmann, Shannon A. Heinig et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  58. RESEARCH CHALLENGES IN STAGE III AND IV RAS-ASSOCIATED CANCERS: A Narrative Review of the Complexities and Functions of the Family of RAS Genes and Ras Proteins in Housekeeping and Tumorigenesis
    Richard A. McDonald, Armando Varela-Ramı́rez, Amanda K. Ashley · 2025 · Biology
  59. Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer
    Linsha Zhu, Xiangbo Jia, Lei Xu, Li Chen, Xiangning Fu, Hua Yan, Bo Ai, Shu Peng · 2025 · iScience
  60. Development of Scalable Synthesis of RAS Inhibitor’s Indole Building Block via Flow Chemistry
    Sudarshan Debnath, Wencun Wang, Songren Xue, Shovan Mondal, Xingyong Zhu · 2025 · Organic Process Research & Development
  61. Induction of MAP kinase phosphatase 3 through Erk/MAP kinase activation in three oncogenic Ras (H-, K- and N-Ras)-expressing NIH/3T3 mouse embryonic fibroblast cell lines
    JaeHyung Koo, Sen Wang, NaNa Kang, Sun Jin Hur, Young Yil Bahk · 2016 · BMB Reports
  62. Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition
    Lo Lai, Viviane Brel, Kanika Sharma, Julia Frappier, Nadia Le-Henanf, Bertrand Vivet, Nicolas Muzet, Emilie Schell, Renaud Morales, E.K. Rooney et al. · 2021 · SLAS DISCOVERY
  63. Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors
    Priyanka Sahu, Ankita Mitra, Anirban Ganguly · 2024 · International review of cytology
  64. The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis
    Yujie Huang, Daitian Zheng, Zhongming Zhou, Haiting Wang, Yanpo Li, Huihui Zheng, Jianhui Tan, Jingyao Wu, Qiuping Yang, Huiting Tian et al. · 2024 · Frontiers in Oncology
  65. Cancer research is not correlated with driver gene mutation burdens
    Gaurav Mendiratta, David Liarakos, Melinda M. Tong, Satoko Ito, Eugene Ke, George Goshua, Edward C. Stites · 2024 · Med
  66. Design, synthesis, and evaluation of dual son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR) inhibitors for the treatment of cancers
    Yi Zeng, Chenyang Huang, Qiangqiang Hou, Wenhua Jiang, Jiaqi Cheng, Xiaoxing Wu · 2024 · Bioorganic Chemistry
  67. The prominent pervasive oncogenic role and tissue specific permissiveness of RAS gene mutations
    Ming Yi, Daniel R. Soppet, Frank P. McCormick, Dwight V. Nissley · 2024 · Scientific Reports
  68. Nanoparticles Bounded to Interfering RNAs as a Therapy for Pancreatic Cancer: A Systematic Review
    Patricia Lara, Francisco Quiñonero, Raúl Ortíz, Jose Carlos Prados, Consolación Melguizo · 2024 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
  69. Unraveling atomic-scale mechanisms of GDP extraction catalyzed by SOS1 in KRAS-G12 and KRAS-D12 oncogenes
    Zheyao Hu, Jordi Martí · 2024 · Computers in Biology and Medicine
  70. The Effect of Phosphoserine-Containing Membranes on Electrostatic Fields at the Protein–Protein Interface Measured through Vibrational Stark Effect Spectroscopy
    Jackson C. Fink, Lauren J. Webb · 2025 · Biochemistry
  71. In silico analysis of wild-type and mutant KRAS
    Frengki Frengki, Deddi Prima Putra, Fatma Sriwahyuni, Daan Khambri, Henni Vanda · 2019 · Pharmaciana
  72. Immediate and Selective Control of Protein Abundance Using the dTAG System
    Behnam Nabet, Nathanael S. Gray · 2020 · Royal Society of Chemistry eBooks
  73. New Avenue to Inhibit Ras Signaling
    Xosé R. Bustelo · 2014 · Chemistry & Biology
  74. Divide and conquer
    Matthew T. Holderfield, Deborah K. Morrison · 2016 · Nature Chemical Biology
  75. Exploring binding modes of the selected inhibitors to phosphodiesterase delta by all-atom molecular dynamics simulations and free energy calculations
    Hui Zhong, Yanjun Zhang, Xiaobin Shan · 2018 · Journal of Biomolecular Structure and Dynamics
  76. Molecular mechanism of the association and dissociation of Deltarasin from the heterodimeric KRas4B‐PDEδ complex
    Martiniano Bello, José Correa‐Basurto, Miguel Angel Vargas · 2019 · Biopolymers
  77. Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
    Constance Agamasu, Peter H. Frank, Shelley C. Perkins, Timothy J. Waybright, Simon A. J. Messing, William Gillette, Andrew G. Stephen · 2020 · Journal of Visualized Experiments
  78. Regulation of ARL2 in colorectal cancer cell proliferation and tumorigenicity, and its negative association with AXL
    Xunlei Pang, Yanhong Wang, Bei Miao, Sujuan Fei, Weichang Chen · 2021 · Oncology Letters
  79. The frequency of somatic mutations in cancer predicts the phenotypic relevance of germline mutations
    E. Draetta, D. Lazarević, P. Provero, Davide Cittaro · 2023 · Frontiers in Genetics
  80. Extracellular Signal-Regulated Kinase (ERK1 and ERK2) Inhibitors
    Ahmed A. Samatar · 2016 · Elsevier eBooks
  81. The Effective Targeting of KRASG12C Elusiveness
    Elena Élez, Josep M. Tabernero · 2020 · Cancer Cell
  82. Absolute Quantitation of GTPase Protein Abundance
    Fiona E. Hood, Yasmina M. E. Sahraoui, Rosalind E. Jenkins, Ian A. Prior · 2021 · Methods in molecular biology
  83. A computational panel of pathological RAS mutants with implications for personalized medicine and genetic medicine
    Chelsey Kenney, Edward C. Stites · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
  84. Developing Small Molecules that Inhibit K-Ras/GTP Binding Based on New Affinity Measurements
    Luca Carta, Rebecca Hutcheson, Simon A. Davis, Michael J. Rudolph, Charles H. Reynolds, Matthias Quick, Theresa M. Williams, Michael Schmertzler, Yaron R. Hadari · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  85. Exploiting KRAS-Driven Ferroaddiction in Cancer Through Ferrous Iron-Activatable Drug Conjugates (FeADC)
    Honglin Jiang, Ryan K. Muir, Ryan L. Gonciarz, Adam B. Olshen, Iwei Yeh, Byron C. Hann, Ning Zhao, Yung-Hua Wang, Spencer C. Behr, Michael J. Evans et al. · 2020 · SSRN Electronic Journal
  86. Multiplexed identification of RAS paralog imbalance as a driver of lung cancer growth
    Rui Tang, Emily G. Shuldiner, Marcus R. Kelly, Christopher W. Murray, Jess D. Hebert, Laura Andrejka, Min K. Tsai, Nicholas W. Hughes, Mitchell I. Parker, Hongchen Cai et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  87. Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models
    Daniela Farias de Nóbrega, Logan C. Eiler, Parmanand Ahirwar, Urvi P. Rawal, Chelsea L. Crawford, Donald J. Buchsbaum, Adam B. Keeton, Yulia Y. Maxuitenko, Xi Chen, Gary Anthony Piazza et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  88. Biophysical and Biochemical Characterization of Structurally Diverse Small Molecule Hits for KRAS Inhibition
    Cynthia V. Pagba, Amit Kumar Gupta, K. M. Dilsha, Parisa Sadrpour, Jacob L. Jakubec, Priyanka Prakash, Dharini van der Hoeven, Kwang‐Jin Cho, Scott R. Gilbertson, Alemayehu Abebe Gorfe · 2024 · ChemBioChem
  89. Exploring the Role of PROTACs for the Treatment of Breast Cancer
    Arzoo Singh Pannu, Ramesh K. Goyal, Shikha Goswami · 2024 · Springer eBooks
  90. Current Understanding on Impact of Kirsten Rat Sarcoma Viral Oncogene Mutation on Colorectal Cancer: A Review
    Shampa Pakhira, Priya Samanta, Rituparna Ghosh, Mrinmoyee Mondal, Souradeep Biswas, Rupali Sarkar, Arijit Bhowmik, Prosenjit Saha, Subhadip Hajra · 2024 · Journal of Current Oncological Trends
  91. Unimolecular Micelle for MLN8237 Delivery to Target AURKA-RalA Crosstalk for Ras-Driven Tumor Suppression in Mice Xenografts
    Kajal Singh, Shahidkhan Pathan, Mehak Malhotra, M. Jayakannan, Nagaraj Balasubramanian · 2025 · Biomacromolecules
  92. RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types
    Zahra Davoudi, Thomas Steven Dexheimer, Nathan P. Coussens, Thomas E. Silvers, Raymond G. Fox, Samantha B. Kemp, Poorva Juneja, Joel Morris, Melinda G. Hollingshead, Naoko Takebe et al. · 2025 · Cancer Research Communications
  93. Integrated methylome analysis identifies an epigenetically silenced tumor suppressor RASA4 in small cell lung cancer
    Meng Fu, Qizhi Zhu, Jian Qi, Xiaopeng Zhang, Zhipeng Wang, Jialiang Wang, Xiang Huang, Zongtao Hu, Wei Wang, Bo Hong et al. · 2025 · Communications Biology
  94. Systems-level consequences of low RAF abundance for EGFR-ERK signaling
    Sung Hyun Lee, Paul J. Myers, Max C. Mendrzycki, Kevin Brown, Leslie M. Loew, Alexander D. Sorkin, Matthew J. Lazzara · 2026 · Biophysical Journal
  95. KRAS4a and KRAS4b show distinct lipid-dependent regulation of RAS-RAF membrane dynamics
    Konstantia Georgouli, Jeremy O. B. Tempkin, Liam G. Stanton, Tomas Oppelstrup, Rebika Shrestha, Timothy S. Carpenter, Fikret Aydin, Xiaohua Zhang, Harsh Bhatia, Yue Yang et al. · 2026 · Journal of Biological Chemistry
  96. Disulfide tethering reveals cryptic pockets in oncogenic KRAS
    Trent E. Balius, Marcin D. Dyba, Vandana Kumari, J. L. Denson, Ming Yi, Alok Kumar Sharma, Priyanka Prakash, Emily O. Alberico, Simon A. J. Messing, Vanessa E. Wall et al. · 2026 · Communications Chemistry
  97. A ternary association of KRas, EphA2, and integrins controls PDAC cell behavior
    Mahak Fatima, Nasir Haider, Stuart A. Cain, Bipul R. Acharya, Megan R. Chastney, Junzhe Zha, Matt Jones, Stacey Warwood, David Knight, Derek A O'Reilly et al. · 2026 · Journal of Biological Chemistry
  98. Changes in the transcriptome and synthetic lethal dependencies following KRAS mutant expression reveal profound tissue specificity
    Timothy D. Martin, Mei Yuk Choi, Julia C. McBride, Stephen Joseph Elledge · 2026 · Proceedings of the National Academy of Sciences
  99. Glutamate E15 and E171 are Hotspots in p60TRP-Related Cancer
    Arne Kutzner, Klaus Heese · 2016 · Cancer Investigation
  100. Mechanisms of l-Arginine-Auxotrophic Response and Their Cancer Therapeutic Implications
    Wen-Bin Tsai, Yan Long, Niramol Savaraj, Lynn G. Feun, Macus Tien Kuo · 2016 · Springer eBooks